Show simple item record

dc.contributor.authorVega Rocha, Yolanda 
dc.contributor.authorDelgado, Elena 
dc.contributor.authorFernández-García, Aurora 
dc.contributor.authorCuevas, Maria Teresa 
dc.contributor.authorThomson, Michael M 
dc.contributor.authorMontero, Vanessa 
dc.contributor.authorSanchez-Martinez, Monica 
dc.contributor.authorSánchez, Ana Maria
dc.contributor.authorPerez-Alvarez, Lucia 
dc.date.accessioned2018-12-28T10:32:20Z
dc.date.available2018-12-28T10:32:20Z
dc.date.issued2015-05-26
dc.identifier.citationPLoS One. 2015 May 26;10(5):e0125699es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6972
dc.description.abstractOur objectives were to carry out an epidemiological surveillance study on transmitted drug resistance (TDR) among individuals newly diagnosed of HIV-1 infection during a nine year period in Spain and to assess the role of transmission clusters (TC) in the propagation of resistant strains. An overall of 1614 newly diagnosed individuals were included in the study from January 2004 through December 2012. Individuals come from two different Spanish regions: Galicia and the Basque Country. Resistance mutations to reverse transcriptase inhibitors (RTI) and protease inhibitors (PI) were analyzed according to mutations included in the surveillance drug-resistance mutations list updated in 2009. TC were defined as those comprising viruses from five or more individuals whose sequences clustered in maximum likelihood phylogenetic trees with a bootstrap value ≥90%. The overall prevalence of TDR to any drug was 9.9%: 4.9% to nucleoside RTIs (NRTIs), 3.6% to non-nucleoside RTIs (NNRTIs), and 2.7% to PIs. A significant decrease of TDR to NRTIs over time was observed [from 10% in 2004 to 2% in 2012 (p=0.01)]. Sixty eight (42.2%) of 161 sequences with TDR were included in 25 TC composed of 5 or more individuals. Of them, 9 clusters harbored TDR associated with high level resistance to antiretroviral drugs. T215D revertant mutation was transmitted in a large cluster comprising 25 individuals. The impact of epidemiological networks on TDR frequency may explain its persistence in newly diagnosed individuals. The knowledge of the populations involved in TC would facilitate the design of prevention programs and public health interventions.es_ES
dc.description.sponsorshipThis work was supported by Consellería de Sanidade, Government of Galicia, Spain (MVI -1291/08), Osakidetza-Servicio Vasco de Salud, Basque Country, Spain (MVI-1255-08) and Ministerio de Sanidad, Servicios Sociales e Igualdad, Dirección General de Salud Pública, Cohesión e Innovación (PI EC11-272). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Sciencees_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult es_ES
dc.subject.meshCluster Analysis es_ES
dc.subject.meshDrug Resistance, Viral es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGenotype es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHIV Protease es_ES
dc.subject.meshHIV Protease Inhibitors es_ES
dc.subject.meshHIV Reverse Transcriptase es_ES
dc.subject.meshHIV-1 es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshPhylogeny es_ES
dc.subject.meshPrevalence es_ES
dc.subject.meshReverse Transcriptase Inhibitors es_ES
dc.subject.meshSpain es_ES
dc.subject.meshEpidemiological Monitoring es_ES
dc.subject.meshMutation es_ES
dc.titleEpidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutationses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID26010948es_ES
dc.format.volume10es_ES
dc.format.number5es_ES
dc.format.pagee0125699es_ES
dc.identifier.doi10.1371/journal.pone.0125699es_ES
dc.contributor.funderGobierno de Galiciaes_ES
dc.contributor.funderGobierno del País Vascoes_ES
dc.contributor.funderMinisterio de Sanidad, Servicios Sociales e Igualdad (España)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1932-6203es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0125699es_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI EC11-272es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional